ArticlePediatric rheumatology online journal2025
Evaluation of the real-world safety of Canakinumab in the treatment of systemic juvenile idiopathic arthritis in children aged 0-16: a comprehensive analysis based on FAERS data.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCanakinumab is a fully human monoclonal antibody that primarily targets interleukin-1β (IL-1β) and is primarily indicated for systemic juvenile idiopathic arthritis (sJIA). Since it is predominantly used in children aged 0-16 years, exploring its safety in real-world settings is of paramount importance.
methodsThis study evaluated the real-world safety of Canakinumab in clinical practice by analyzing adverse events (AEs) associated with the use of the drug in the 0-16 year age group with sJIA from 2014 to 2023, using data retrieved from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis of relevant AEs was performed via four methods: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the multi-item gamma Poisson shrinker (MGPS), and the Bayesian confidence propagation neural network (BCPNN). Additionally, the Weibull shape parameter (WSP) test distribution was employed to model the risk of AEs over time.
resultsA total of 439 adverse events (AEs) were included in this study. Positive signals were identified for several adverse reactions listed on the drug label, including inappropriate schedule of product administration, incorrect dose administered, rash, illness, gastroenteritis, thrombocytopenia, lymphadenopathy, leukopenia, transaminases increased, aspartate aminotransferase increased and alanine aminotransferase increased. Furthermore, the study identified potential adverse reactions not mentioned on the label, such as hemophagocytic lymphohistiocytosis, COVID-19, nasal congestion and increased serum ferritin. These findings underscore the importance of AE monitoring, particularly emphasizing the value of early detection.
conclusionThis FAERS-based pharmacovigilance study provides preliminary safety data on the use of Canakinumab in children aged 0-16 years with sJIA, confirming several known adverse reactions and revealing additional potential risks. These findings offer clinicians valuable safety information for the use of Canakinumab in the treatment of sJIA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.